Tumor-specific CD8 <sup>+</sup> T cells from the bone marrow resist exhaustion and exhibit increased persistence in tumor-bearing hosts as compared with tumor-infiltrating lymphocytes
T cells from the BM appear superior to TILs as a source of cells for cellular therapy. They possess a memory-enriched phenotype and exhibit improved effector function, greater persistence within a tumor-bearing host, and the capacity for increased tumor infiltration. These data provide a foundation for further exploring the BM as a source of tumor-specific T cells for ACT in solid malignancies.
Authors
- Luca Biavati (ORCID: https://orcid.org/0000-0001-7870-5754)
- Ivan Borrello (ORCID: https://orcid.org/0000-0002-7316-8862)
- Elizabeth Maria Zawidzka
- Robert D. Leone (ORCID: https://orcid.org/0000-0002-1664-0075)
- Luigi Marchionni (ORCID: https://orcid.org/0000-0002-7336-8071)
- Claudio Zanettini (ORCID: https://orcid.org/0000-0001-5043-8033)
- Amy Thomas
Institutions
- Bloomberg (United States) (US)
- Johns Hopkins University (US)
- Cornell University (US)
- Tampa General Hospital (US)
- Sidney Kimmel Cancer Center (US)
- AdventHealth Tampa (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1136/jitc-2024-009367
- Citations
- 3
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 3.14